Last reviewed · How we verify
Spiramycin 2 (Spiramycin II)
Spiramycin 2 (generic name: Spiramycin II) is a Spiramycin II drug. It is currently in unknown development.
Spiramycin II works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins needed for growth and survival.
Spiramycin is a small molecule that inhibits the bacterial 70S ribosome. It is used to treat Toxoplasmosis, as indicated by clinical trials on ClinicalTrials.gov.
At a glance
| Generic name | Spiramycin II |
|---|---|
| Drug class | Spiramycin II |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Think of it like a factory where bacteria make proteins. Spiramycin II blocks the factory's machinery, stopping the bacteria from making the proteins they need to grow and multiply. This ultimately leads to the death of the bacteria, helping to clear up infections.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spiramycin 2 CI brief — competitive landscape report
- Spiramycin 2 updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Spiramycin 2
What is Spiramycin 2?
How does Spiramycin 2 work?
What is the generic name of Spiramycin 2?
What drug class is Spiramycin 2 in?
What development phase is Spiramycin 2 in?
Related
- Drug class: All Spiramycin II drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing